ABGENT（百奇生物）正式加入Wuxi Apptec（药明康德）！

2011年10月14日，WuxiApptec宣布正式收购ABGENT！

Abgent是一家位于苏州、圣迭哥，集研发、生产、销售生物研究用试剂与提供定制服务于一体的生物技术公司。

Abgent成立于2001年，目前是世界上最大抗体生产商之一，并已建立全人类基因抗体库。公司已上市近20000余种抗体，每年推出超过5000个抗体新产品。除了抗体，Abgent还研发生产多肽、蛋白质、CDNA、siRNA等科研和诊断应用试剂。

WuxiApptec作为一家在中美两国均有运营实体的全球领先的制药、生物技术以及医疗器械研发外包服务公司，其服务旨在帮助其全球合作伙伴，如全球制药，生物技术和医疗设备公司，缩短开发周期，降低药品和医疗设备成本。

在过去的十年中，WuxiApptec在制药，生物技术与医疗设备方面为全球客户提供了高品质与低成本的服务，而此次成功收购Abgent，将为WuxiApptec带来了研发领域的新进展，拥有重要的战略意义。

Abgent将借助WuxiApptec在中国的业务优势和技术平台优势，为全球科研人员提供一系列品质更高、种类更齐全的科研诊断试剂。

药明康德官方网站：http://www.wuxiapptec.com

           October2011

WuXiPharmaTech(NYSE:WX),aleADIngpharmaceutical,biotechnology,andmedical-deviceresearchanddevelopmentoutsourcingcompany,withoperationsinChinaandtheUnitedStates,todayannouncedtheacquisitionofAbgent,Inc.,aproviderofBIOLOGicalresearchreagentproductsandservicesbasedinSuzhou,China,andSanDiego,California.

Oct14,2011–Shanghai,China–WuXiPharmaTech(NYSE:WX),aleadingpharmaceutical,biotechnology,andmedical-deviceresearchanddevelopmentoutsourcingcompany,withoperationsinChinaandtheUnitedStates,todayannouncedtheacquisitionofAbgent,Inc.,aproviderofbiologicalresearchreagentproductsandservicesbasedinSuzhou,China,andSanDiego,California.

Foundedin2001,Abgentisalreadyoneoftheworld"slargestmanufacturersofantibodyreagentsforresearchuse.Thecompanymaintainsacomprehensivecatalogofabout20,000antibodyproducts.Abgentalsoservesastheoriginalmanufacturerofantibodiesdistributedbylargereagentsuppliers.Thecompanydistributesitsantibodyreagentproductsbydirectsalesthroughitswebportalandsmallsalesforceandthroughanetworkofdistributorsaroundtheworld.Inadditiontomanufacturingantibodies,Abgentalsodevelopsandproducespeptidesandproteinsforresearchanddiagnosticapplications.

TheacquisitionofAbgentisalogicalextensionofWuXi"ssuccessfulbusinessmodel.WuXihasachievedstronggrowthforthepastdecadebybuildingcapABIlitiesandcapacitiestoprovidehigh-qualityandcost-effectiveservicesforglobalcustomersinthepharmaceutical,biotechnology,andmedical-deviceindustries.AbgentbringstoWuXinewproductlinesofbiologicalresearchreagentsfordrugdiscoveryandbasicresearchtoexpandourserviceofferingtoourexistingcustomersandtonewcustomersinthelife-scienceresearchcommunity.

Abgentutilizesahigh-quality,low-costdevelopmentandproductionbase,operatingstate-of-artfacilitiesconsistingofa34,000square-footlaboratoryinSuzhouanda10,000square-footlaboratoryandofficeinSanDiego.Thecompanyhasabout150employees.Dr.ChunWu,founderandCEOofAbgent,willcontinuetoruntheAbgentbusinessunitpost-acquisitionasVicePresidentofBiologicalReagentProductsandServices.

Thefinancialtermsoftheacquisitionwerenotdisclosed.

"WuXi"sacquisitionofAbgentcontinuesourstrategyleveragingtheadvantagesofourChina-basedoperationstoprovidehigh-qualityservicesandproductsneededbytheworld"sbiopharmaceuticalandscientificresearchers,"saidDr.GeLi,ChairmanandCEOofWuXi."WuXi"smissionistobuildaplatformthatwillallowanyoneandanycompanytodiscoveranddevelopdrugsmoreefficientlyandcosteffectivelyforpatients.UnderChun"sleadership,Abgenthasbuiltasuccessfulintegrateddevelopmentandproductionplatformofcatalogandcustomizedantibodyreagentsfortheglobalresearchreagentmarket.WuXi"sbroadcapabilitiesandcustomerrelationshipscantakeAbgenttothenextlevel.IamveryexcitedaboutthissmallbutstrategicallyimportantacquisitionandlookforwardtoworkingwithChuntobetterthewayfutureresearchreagentswillbesupplied."

"WeatAbgentareexcitedbytheopportunitytojoinWuXiPharmaTechtoachievethevisionofcreatingacomprehensive,integratedR&Dplatformtoservetheworldwidepharmaceuticalindustryandresearchcommunity,"saidDr.Wu,founderandCEOofAbgent.

WuXiPharmaTechisaleadingpharmaceutical,biotechnologyandmedicaldeviceR&Doutsourcingcompany,withoperationsinChinaandtheUnitedStates.Asaresearch-drivenandcustomer-focusedcompany,WuXiPharmaTechprovidespharmaceutical,biotechnologyandmedicaldevicecompanieswithabroadandintegratedportfoliooflaboratoryandmanufacturingservicesthroughoutthedrugandmedicaldeviceR&Dprocess.WuXiPharmaTech"sservicesaredesignedtohelpitsglobalpartnersinshorteningthecycleandloweringthecostofdrugandmedicaldeviceR&D.TheoperatingsubsidiariesofWuXiPharmaTechareknownasWuXiAppTec.

Statementsinthisreleasecontain"forward-looking"statementswithinthemeaningofSection27AoftheSecuritiesActof1933,asamended,andSection21EoftheSecuritiesExchangeActof1934,asamended,andasdefinedinthePrivateSecuritiesLitigationReformActof1995,includingthestrategicrationalefor,andanticipatedbenefitsof,theAbgentacquisitionandtheexpectedgrowthinAbgent"stargetmarket.

Theseforward-lookingstatementsarenothistoricalfactsbutinsteadrepresentonlyourbeliefregardingfutureevents,manyofwhich,bytheirnature,areinherentlyuncertainandoutsideofourcontrol.Ouractualresultsmaydiffer,possIBLymaterially,fromtheanticipatedbenefits,resultsandfinancialcontributionsindicatedintheseforward-lookingstatements.Amongothertransactionspecificfactors,wemaynotrecognizefullytheanticipatedbenefitsofthetransaction,theAbgentbusinessmaynotperform,orAbgent"stargetmarketmaynotgrow,asexpectedandtheremaybeunexpectedcostsordifficultiesinintegratingtheAbgentbusinessorinretainingitsemployeesandmanagement.Inaddition,ourbusinessandindustryfaceotherdifficultiesandrisksincludingthestateoftheglobaleconomymaycontinuetobeuncertain;pharmaceuticalcompaniesmaynotchangetheirbusinessmodelsasexpectedorinamannerfavorabletous;wemayfailtocapitalizeontheopportunitiespresented;thepressuresbeingfeltbyourcustomersandpharmaceuticalindustryconsolidationmayadverselyimpactourbusinessandthetrendsforoutsourcedandoffshoredR&Dandmanufacturingforlongerthanexpectedormoreseverelythanexpected;wemaybeunabletosuccessfullymakeourplannedinvestmentsandcapitalexpendituresonatimelybasis;theseinvestmentsmaynotyieldthedesiredresultsandwemayneedtomodifythenatureandlevelofourinvestmentsandcapitalexpenditures;wemaynotmaintainourpreferredproviderstatuswithourclientsandmaybeunabletosuccessfullyexpandourcapabilitiestomeetclientneeds;andwemayfaceincreasedmarginpressureasaresultofrenminbiappreciationandincreasedlaborinflationinChina.Youshouldreadthefinancialinformationcontainedinthisreleaseinconjunctionwiththeconsolidatedfinancialstatementsandrelatednotestheretoincludedinour2010AnnualReportonForm20-FfiledwiththeSecuritiesandExchangeCommissionandavailableontheSecuritiesandExchangeCommission"swebsiteathttp://www.sec.gov.Foradditionalinformationontheseandotherimportantfactorsthatcouldadverselyaffectourbusiness,financialcondition,resultsofoperationsandProspects,see"RiskFactors"beginningonpage6ofour2010AnnualReportonForm20-F.Allprojectionsinthisreleasearebasedonlimitedinformationcurrentlyavailabletous,whichissubjecttochange.Althoughtheseprojectionsandthefactorsinfluencingthemwilllikelychange,weundertakenoobligationtoupdateorrevisetheseforward-lookingstatements,whetherasaresultofnewinformation,futureeventsorotherwise,afterthedateofthispressrelease,exceptasrequiredbylaw.Suchinformationspeaksonlyasofthedateofthisrelease.

WuXiPharmaTechisaleadingpharmaceutical,biotechnology,andmedicaldeviceR&Doutsourcingcompany,withoperationsinChinaandtheUnitedStates.Asaresearch-drivenandcustomer-focusedcompany,weprovideabroadandintegratedportfoliooflaboratoryandmanufacturingservicesthroughoutthedrugandmedicaldeviceR&Dprocess.Ourservicesaredesignedtohelpourglobalpartnerstoimprovethesuccessofresearchandshortenthetimeofdevelopmentcosteffectivelyindiscoveringanddevelopingdrugsandmedicaldevices.

转自：http://www.abgent.com.cn/docs/pharmatechs_aquires_abgent